GlassScriptPhysician profile
Amanda M Goldstein
NPI 1437329786
$3,245.24
in general payments reported to CMS, 2019-2025
34 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $113 · 2022: $285 · 2023: $536 · 2024: $1,176 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $389.23 | 2022-2025 | |
| Pfizer INC. | $378.29 | 2019-2025 | |
| Novo Nordisk INC | $315.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $232.08 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $205.50 | 2019-2025 | Veozah |
| Lilly USA, LLC | $197.44 | 2019-2024 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $190.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $152.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.33 | 2023-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $120.94 | 2024-2025 | Voquezna |
| Amgen INC. | $101.70 | 2022-2025 | Otezla, Repatha, Prolia |
| Arbor Pharmaceuticals, INC. | $97.98 | 2019 | |
| Exact Sciences Corporation | $91.69 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $85.20 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $81.59 | 2023-2025 | Rexulti, Abilify Asimtufii |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $66.53 | 2023-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $43.43 | 2022-2024 | |
| Axsome Therapeutics, INC. | $40.77 | 2024-2025 | Auvelity |
| Abbott Laboratories | $34.67 | 2022-2025 | Freestyle Libre 3 |
| Almatica Pharma LLC | $28.31 | 2024-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $28.03 | 2022-2023 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.75 | 2019-2022 | |
| Verona Pharma, INC. | $22.77 | 2025 | Ohtuvayre |
| Corium, LLC | $19.82 | 2025 | Azstarys |
| Averitas Pharma INC. | $18.37 | 2025 | Qutenza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.83 | 2022 | |
| Dexcom, INC. | $16.97 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $16.96 | 2024 | |
| Sanofi Pasteur INC. | $16.80 | 2022 | |
| Medtronic, INC. | $15.44 | 2024 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $15.18 | 2025 | Jornay Pm |
| Amneal Pharmaceuticals LLC | $15.16 | 2023 | Unithroid |
| Janssen Pharmaceuticals, INC | $11.79 | 2019 | |
| Merck Sharp & Dohme LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.